Your browser doesn't support javascript.
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
Kumari, Monika; Lu, Ruei-Min; Li, Mu-Chun; Huang, Jhih-Liang; Hsu, Fu-Fei; Ko, Shih-Han; Ke, Feng-Yi; Su, Shih-Chieh; Liang, Kang-Hao; Yuan, Joyce Pei-Yi; Chiang, Hsiao-Ling; Sun, Cheng-Pu; Lee, I-Jung; Li, Wen-Shan; Hsieh, Hsing-Pang; Tao, Mi-Hua; Wu, Han-Chung.
  • Kumari M; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Lu RM; Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang District, Taipei, 11529, Taiwan.
  • Li MC; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Huang JL; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Hsu FF; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Ko SH; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Ke FY; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Su SC; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Liang KH; Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang District, Taipei, 11529, Taiwan.
  • Yuan JP; Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang District, Taipei, 11529, Taiwan.
  • Chiang HL; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Sun CP; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Lee IJ; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Li WS; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Hsieh HP; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.
  • Tao MH; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan.
  • Wu HC; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.
J Biomed Sci ; 29(1): 68, 2022 Sep 12.
Article in English | MEDLINE | ID: covidwho-2021289
ABSTRACT
The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has designed vaccines, diagnostic tools and therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The rapid pace of technology development, especially with regard to vaccines, represents a stunning and historic scientific achievement. Nevertheless, many challenges remain to be overcome, such as improving vaccine and drug treatment efficacies for emergent mutant strains of SARS-CoV-2. Outbreaks of more infectious variants continue to diminish the utility of available vaccines and drugs. Thus, the effectiveness of vaccines and drugs against the most current variants is a primary consideration in the continual analyses of clinical data that supports updated regulatory decisions. The first two vaccines granted Emergency Use Authorizations (EUAs), BNT162b2 and mRNA-1273, still show more than 60% protection efficacy against the most widespread current SARS-CoV-2 variant, Omicron. This variant carries more than 30 mutations in the spike protein, which has largely abrogated the neutralizing effects of therapeutic antibodies. Fortunately, some neutralizing antibodies and antiviral COVID-19 drugs treatments have shown continued clinical benefits. In this review, we provide a framework for understanding the ongoing development efforts for different types of vaccines and therapeutics, including small molecule and antibody drugs. The ripple effects of newly emergent variants, including updates to vaccines and drug repurposing efforts, are summarized. In addition, we summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 strains.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Biomed Sci Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: S12929-022-00852-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Biomed Sci Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: S12929-022-00852-9